HC Wainwright set a $8.00 price objective on Immune Design (NASDAQ:IMDZ) in a report issued on Friday morning, The Fly reports. The firm currently has a buy rating on the biotechnology company’s stock.
IMDZ has been the subject of several other reports. Zacks Investment Research raised shares of Immune Design from a hold rating to a buy rating and set a $5.00 price objective for the company in a research report on Tuesday, June 19th. Royal Bank of Canada reaffirmed an outperform rating and set a $11.00 price objective on shares of Immune Design in a research report on Friday. Finally, Leerink Swann cut shares of Immune Design from an outperform rating to a market perform rating in a research report on Friday. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Immune Design has an average rating of Buy and an average price target of $8.40.
Shares of NASDAQ:IMDZ traded down $0.94 during trading on Friday, hitting $1.85. The company’s stock had a trading volume of 3,329,086 shares, compared to its average volume of 342,327. The company has a market cap of $166.17 million, a price-to-earnings ratio of -1.06 and a beta of 1.77. Immune Design has a fifty-two week low of $1.47 and a fifty-two week high of $11.05.
Immune Design (NASDAQ:IMDZ) last posted its quarterly earnings results on Wednesday, August 1st. The biotechnology company reported ($0.29) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.30) by $0.01. The business had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.64 million. Immune Design had a negative net margin of 2,324.21% and a negative return on equity of 46.95%. As a group, research analysts expect that Immune Design will post -1.25 earnings per share for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in IMDZ. Portolan Capital Management LLC purchased a new stake in shares of Immune Design during the 2nd quarter worth $2,024,000. Dimensional Fund Advisors LP lifted its position in shares of Immune Design by 132.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 447,026 shares of the biotechnology company’s stock worth $2,034,000 after purchasing an additional 254,696 shares during the last quarter. BlackRock Inc. lifted its position in shares of Immune Design by 10.6% during the 2nd quarter. BlackRock Inc. now owns 2,121,271 shares of the biotechnology company’s stock worth $9,651,000 after purchasing an additional 204,171 shares during the last quarter. Alps Advisors Inc. purchased a new stake in shares of Immune Design during the 2nd quarter worth $318,000. Finally, Essex Investment Management Co. LLC purchased a new stake in shares of Immune Design during the 2nd quarter worth $192,000. 49.41% of the stock is owned by institutional investors and hedge funds.
Immune Design Company Profile
Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma.
Recommended Story: What is a Call Option?
Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.